Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery? (Q36381266)

13 August 2017

1 reference

title

Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery? (English)

1 reference

13 August 2017

1 reference

Catherine A O'Brian

1

1 reference

13 August 2017

Feng Chu

series ordinal

2

1 reference

13 August 2017

William G Bornmann

series ordinal

3

1 reference

13 August 2017

David S Maxwell

series ordinal

4

1 reference

13 August 2017

publication date

1 February 2006

1 reference

Expert Review of Anticancer Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

175-186

1 reference

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Cellular homologue (c-src) of the transforming gene of Rous sarcoma virus: isolation, mapping, and transcriptional analysis of c-src and flanking regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

21 January 2018

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Gefitinib--a novel targeted approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Targeting protein kinases in cancer therapy: a success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

A synthetic inhibitor of the mitogen-activated protein kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

New approaches in identifying drugs to inactivate oncogene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Opportunities and challenges in the development of kinase inhibitor therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Emerging and diverse roles of protein kinase C in immune cell signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase C-alpha-induced hypertrophy of neonatal rat ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase cascades in the regulation of cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase C isozymes as potential targets for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase C alpha expression in breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase C-alpha in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

The role of protein kinase C-alpha (PKC-alpha) in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Telomerase is controlled by protein kinase Calpha in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Identification of an inactivating cysteine switch in protein kinase Cepsilon, a rational target for the design of protein kinase Cepsilon-inhibitory cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Cellular protein kinase C isozyme regulation by exogenously delivered physiological disulfides--implications of oxidative protein kinase C regulation to cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

PKC sulfhydryl targeting by disulfiram produces divergent isozymic regulatory responses that accord with the cancer preventive activity of the thiuram disulfide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Catalytic domain crystal structure of protein kinase C-theta (PKCtheta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Ligand-protein docking: cancer research at the interface between biology and chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Structural bioinformatics-based design of selective, irreversible kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Taxol induces caspase-10-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

First-in-class pan caspase inhibitor developed for the treatment of liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Regulation of cAMP-dependent protein kinase activity by glutathionylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Active and inactive protein kinases: structural basis for regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Covalent modification of protein kinase C isozymes by the inactivating peptide substrate analog N-biotinyl-Arg-Arg-Arg-Cys-Leu-Arg-Arg-Leu. Evidence that the biotinylated peptide is an active-site affinity label

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Irreversible inactivation of protein kinase C by a peptide-substrate analog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

PKC isozyme S-cysteinylation by cystine stimulates the pro-apoptotic isozyme PKC delta and inactivates the oncogenic isozyme PKC epsilon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

ESPript: analysis of multiple sequence alignments in PostScript

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

Swiss-PDB Viewer (Deep View).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.175

21 January 2018

Identifiers

DOI

10.1586/14737140.6.2.175

1 reference

13 August 2017

1 reference